Advanced search
Publication Cover
Postgraduate Medicine Volume 125, 2013 - Issue 6
Submit an article Journal homepage
19
Views
0
CrossRef citations to date
0
Altmetric
Oncology Roundtable

A Urologic Oncology Roundtable Discussion: How to Choose Among the Available Therapies for the Treatment of Castration-Resistant Prostate Cancer

Charles Ryan Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CACorrespondence[email protected]
, MD,
Neal D. Shore Carolina Urologic Research Center, Myrtle Beach, SC
, MD, FACS &
Raoul Concepcion Director of Clinical Research, Urology Associates, Nashville, TN
, MD, FACS
Pages 114-116 | Published online: 13 Mar 2015

References

  • . Mostaghel EA, Page ST, Lin DW, . Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033–5041
  • . Mohler JL, Armstrong AJ, Bahnson RR, . NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2013. http://www.NCCN.org. Accessed March 11, 2013
  • . Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245
  • . de Bono JS, Oudard S, Ozguroglu M; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154
  • . Kantoff PW, Higano CS, Shore ND; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422
  • . de Bono JS, Logothetis CJ, Molina A, . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995
  • . Ryan CJ, Smith MR, de Bono JS; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138
  • . Scher HI, Fizazi K, Saad F; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187
  • . Sartor AO, Heinrich D, O'Sullivan JM, . Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA) [abstract]. J Clin Oncol. 2012;30( Suppl):Abstract 4551
  • . Sartor O, Coleman RE, Nilsson S, . Safety of cytotoxic chemotherapy following radium-233 dichloride therapy in the phase 3 ALSYMPCA study in patients with castration-resistant prostate (CRPC) with bone metastases. Poster presented at: ESMO 2012 Congress; September 28–October 2, 2012; Vienna, Austria

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.